With its human immune system, Kymouse™ does much of the difficult work in honing the best therapeutic antibody, suggest Kymab CEO Christian Grøndahl and COO Glenn Friedrich in the April 2014 issue of MedNous.
They explain that, as well as rapidly discovering and developing therapeutic antibodies, Kymouse™ technology can be used to remove the mouse equivalent of the target human protein, improving efficiency and lead times in developing novel therapies. Additional time savings could be realised by combining the Kymouse™ approach with patient genetic and genomic information, to optimise the likelihood of detecting a signal.
Read the MedNous Commentary "A scenario for shortening drug development times "
You'll need the free Adobe Reader to view the PDF article.